Researchers have identified patterns of neuropsychiatric symptoms that may reveal when Alzheimer’s disease occurs alongside ...
Scientists from Johns Hopkins Medicine report new evidence that clusters of brain tissue derived from the cells of patients ...
People have no control over Alzheimer's risk factors such as age, genes and family history. Diet, exercise and adequate sleep ...
Alzheimer’s disease, the leading cause of dementia, is a multifactorial disorder involving amyloid beta (Aβ) and tau ...
Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...
Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
SGMC Health now offers an FDA-approved treatment option for people in the early stages of Alzheimer’s disease, giving ...
Alzheimer’s Society responds to Cochrane review of ‘Amyloid-beta-targeting monoclonal antibodies for people with mild ...
Researchers at the University of California San Diego have uncovered new insights into one of Alzheimer's disease's most ...
Morning Overview on MSN
Major review finds limited benefits from new Alzheimer’s drugs hailed as breakthroughs
For the roughly 6.9 million Americans living with Alzheimer’s disease, the arrival of drugs that target amyloid plaques in ...
Morning Overview on MSN
Alzheimer’s drugs touted as breakthroughs deliver mixed real-world results
When the first drugs capable of slowing Alzheimer’s disease won FDA approval, the moment was hailed as a turning point for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results